Omar Dzaye1, Zeina A Dardari2, Miguel Cainzos-Achirica2, Ron Blankstein3, Arthur S Agatston4, Matthias Duebgen5, Joseph Yeboah6, Moyses Szklo7, Matthew J Budoff8, Joao A C Lima9, Roger S Blumenthal2, Khurram Nasir10, Michael J Blaha11. 1. Johns Hopkins Ciccarone Center for Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Department of Radiology and Neuroradiology, Charité, Berlin, Germany. 2. Johns Hopkins Ciccarone Center for Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 3. Cardiovascular Imaging Program, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. 4. Department of Medicine, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida, USA. 5. Department of Radiology and Neuroradiology, Charité, Berlin, Germany. 6. Heart and Vascular Center of Excellence, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA. 7. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. 8. Department of Medicine, Harbor-University of California Los Angeles Medical Center, Torrance, California, USA. 9. Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 10. Division of Cardiovascular Prevention and Wellness, Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA. 11. Johns Hopkins Ciccarone Center for Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Electronic address: mblaha1@jhmi.edu.
Abstract
OBJECTIVES: This study sought to quantify and model conversion of a normal coronary artery calcium (CAC) scan to an abnormal CAC scan. BACKGROUND: Although the absence of CAC is associated with excellent prognosis, progression to CAC >0 confers increased risk. The time interval for repeated scanning remains poorly defined. METHODS: This study included 3,116 participants from the MESA (Multi-Ethnic Study of Atherosclerosis) with baseline CAC = 0 and follow-up scans over 10 years after baseline. Prevalence of incident CAC, defined by thresholds of CAC >0, CAC >10, or CAC >100, was calculated and time to progression was derived from a Weibull parametric survival model. Warranty periods were modeled as a function of sex, race/ethnicity, cardiovascular risk, and desired yield of repeated CAC testing. Further analysis was performed of the proportion of coronary events occurring in participants with baseline CAC = 0 that preceded and followed repeated CAC testing at different time intervals. RESULTS: Mean participants' age was 58 ± 9 years, with 63% women, and mean 10-year cardiovascular risk of 14%. Prevalence of CAC >0, CAC >10, and CAC >100 was 53%, 36%, and 8%, respectively, at 10 years. Using a 25% testing yield (number needed to scan [NNS] = 4), the estimated warranty period of CAC >0 varied from 3 to 7 years depending on sex and race/ethnicity. Approximately 15% of participants progressed to CAC >10 in 5 to 8 years, whereas 10-year progression to CAC >100 was rare. Presence of diabetes was associated with significantly shorter warranty period, whereas family history and smoking had small effects. A total of 19% of all 10-year coronary events occurred in CAC = 0 prior to performance of a subsequent scan at 3 to 5 years, whereas detection of new CAC >0 preceded 55% of future events and identified individuals at 3-fold higher risk of coronary events. CONCLUSIONS: In a large population of individuals with baseline CAC = 0, study data provide a robust estimation of the CAC = 0 warranty period, considering progression to CAC >0, CAC >10, and CAC >100 and its impact on missed versus detectable 10-year coronary heart disease events. Beyond age, sex, race/ethnicity, diabetes also has a significant impact on the warranty period. The study suggests that evidence-based guidance would be to consider rescanning in 3 to 7 years depending on individual demographics and risk profile.
OBJECTIVES: This study sought to quantify and model conversion of a normal coronary artery calcium (CAC) scan to an abnormal CAC scan. BACKGROUND: Although the absence of CAC is associated with excellent prognosis, progression to CAC >0 confers increased risk. The time interval for repeated scanning remains poorly defined. METHODS: This study included 3,116 participants from the MESA (Multi-Ethnic Study of Atherosclerosis) with baseline CAC = 0 and follow-up scans over 10 years after baseline. Prevalence of incident CAC, defined by thresholds of CAC >0, CAC >10, or CAC >100, was calculated and time to progression was derived from a Weibull parametric survival model. Warranty periods were modeled as a function of sex, race/ethnicity, cardiovascular risk, and desired yield of repeated CAC testing. Further analysis was performed of the proportion of coronary events occurring in participants with baseline CAC = 0 that preceded and followed repeated CAC testing at different time intervals. RESULTS: Mean participants' age was 58 ± 9 years, with 63% women, and mean 10-year cardiovascular risk of 14%. Prevalence of CAC >0, CAC >10, and CAC >100 was 53%, 36%, and 8%, respectively, at 10 years. Using a 25% testing yield (number needed to scan [NNS] = 4), the estimated warranty period of CAC >0 varied from 3 to 7 years depending on sex and race/ethnicity. Approximately 15% of participants progressed to CAC >10 in 5 to 8 years, whereas 10-year progression to CAC >100 was rare. Presence of diabetes was associated with significantly shorter warranty period, whereas family history and smoking had small effects. A total of 19% of all 10-year coronary events occurred in CAC = 0 prior to performance of a subsequent scan at 3 to 5 years, whereas detection of new CAC >0 preceded 55% of future events and identified individuals at 3-fold higher risk of coronary events. CONCLUSIONS: In a large population of individuals with baseline CAC = 0, study data provide a robust estimation of the CAC = 0 warranty period, considering progression to CAC >0, CAC >10, and CAC >100 and its impact on missed versus detectable 10-year coronary heart disease events. Beyond age, sex, race/ethnicity, diabetes also has a significant impact on the warranty period. The study suggests that evidence-based guidance would be to consider rescanning in 3 to 7 years depending on individual demographics and risk profile.
Authors: Yi Xue; Min Wen Zheng; Yang Hou; Fan Zhou; Jian Hua Li; Yi Ning Wang; Chun Yu Liu; Chang Sheng Zhou; Jia Yin Zhang; Meng Meng Yu; Bo Zhang; Dai Min Zhang; Yan Yi; Lei Xu; Xiu Hua Hu; Guang Ming Lu; Chun Xiang Tang; Long Jiang Zhang Journal: Eur Radiol Date: 2022-01-12 Impact factor: 5.315
Authors: Miguel Cainzos-Achirica; Isaac Acquah; Zeina Dardari; Reed Mszar; Philip Greenland; Ron Blankstein; Marcio Bittencourt; Sanjay Rajagopalan; Sadeer G Al-Kindi; Joseph F Polak; Roger S Blumenthal; Michael J Blaha; Khurram Nasir Journal: Am J Cardiol Date: 2021-12-15 Impact factor: 2.778
Authors: Pavithra S Jayadeva; Stephen Stowers; E W Tang; Joao Vitola; Rodrigo Cerci; Jessica Yao; James Westcott; Barry Elison; Nathan Better Journal: J Nucl Cardiol Date: 2022-09-12 Impact factor: 3.872
Authors: Francesco Castagna; Jeremy Miles; Javier Arce; Ephraim Leiderman; Patrick Neshiwat; Paul Ippolito; Patricia Friedmann; Aldo Schenone; Lili Zhang; Carlos J Rodriguez; Michael J Blaha; Jeffrey M Levsky; Mario J Garcia; Leandro Slipczuk Journal: Circ Cardiovasc Imaging Date: 2022-06-21 Impact factor: 8.589
Authors: Jian H Chu; Erin D Michos; Pamela Ouyang; Dhananjay Vaidya; Roger S Blumenthal; Matthew J Budoff; Michael J Blaha; Seamus P Whelton Journal: Am J Prev Cardiol Date: 2022-06-13
Authors: Omar Dzaye; Alexander C Razavi; Erin D Michos; Martin Bødtker Mortensen; Zeina A Dardari; Khurram Nasir; Albert D Osei; Allison W Peng; Ron Blankstein; John H Page; Michael J Blaha Journal: Atherosclerosis Date: 2022-02-12 Impact factor: 6.847
Authors: Omar Dzaye; Alexander C Razavi; Zeina A Dardari; Leslee J Shaw; Daniel S Berman; Matthew J Budoff; Michael D Miedema; Khurram Nasir; Alan Rozanski; John A Rumberger; Carl E Orringer; Sidney C Smith; Ron Blankstein; Seamus P Whelton; Martin Bødtker Mortensen; Michael J Blaha Journal: J Am Coll Cardiol Date: 2021-10-19 Impact factor: 27.203
Authors: Mahmoud Al Rifai; Michael J Blaha; Vijay Nambi; Steven J C Shea; Erin D Michos; Roger S Blumenthal; Christie M Ballantyne; Moyses Szklo; Philip Greenland; Michael D Miedema; Khurram Nasir; Jerome I Rotter; Xiuqing Guo; Jie Yao; Wendy S Post; Salim S Virani Journal: Circulation Date: 2021-12-08 Impact factor: 29.690
Authors: Tony Dong; Graham Bevan; David A Zidar; Miguel Cainzos Achirica; Khurram Nasir; Imran Rashid; Sanjay Rajagopalan; Sadeer Al-Kindi Journal: Pathog Immun Date: 2021-12-03